8 8 3 l e t t e r S Obesity-related hypertension has become an epidemic health problem and a major risk factor for the development of cardiovascular disease (CVD). Recent research on the pathophysiology of obesity has implicated a role for the hypothalamus in the pathogenesis of this condition 1-3 . However, it remains unknown whether the often-seen coupling of hypertension with obesity can also be explained by hypothalamic dysfunction, despite the emerging appreciation that many forms of hypertension are neurogenic in origin 4-13 . Our studies here revealed that acute activation of the proinflammatory protein nuclear factor kB (NF-kB) and its upstream activator IkB kinase-b (IKK-b, encoded by Ikbkb) in the mediobasal hypothalamus rapidly elevated blood pressure in mice independently of obesity. This form of hypothalamic inflammation-induced hypertension involved the sympathetic upregulation of hemodynamics and was reversed by sympathetic suppression. Loss-of-function studies further showed that NF-kB inhibition in the mediobasal hypothalamus counteracted obesity-related hypertension in a manner that was dissociable from changes in body weight. In addition, we found that pro-opiomelanocortin (POMC) neurons were crucial for the hypertensive effects of the activation of hypothalamic IKK-b and NF-kB, which underlie obesity-related hypertension. In conclusion, obesity-associated activation of IKK-b and NF-kB in the mediobasal hypothalamus-particularly in the hypothalamic POMC neurons-is a primary pathogenic link between obesity and hypertension. Breaking this pathogenic link may represent an avenue for controlling obesity-related hypertension and CVD without requiring obesity control.
Chronic inflammation is a common feature of both obesity [14] [15] [16] [17] [18] [19] [20] and hypertension [21] [22] [23] . The molecular pathways that mediate obesityassociated inflammation include IKK-β and NF-κB 14, 24, 25 . Various recent studies have shown that IKK-β and NF-κB activation in peripheral metabolic tissues can cause diverse types of metabolic dysregulations 14, 24, 25 . Most recently, it was shown that IKK-β and NF-κB in the hypothalamus can be activated under obesogenic conditions to promote energy, body weight and glucose imbalance [26] [27] [28] . Here we investigated whether obesity and hypertension can be mechanistically coupled by IKK-β and NF-κB activation in the hypothalamus, and whether hypothalamic IKK-β and NF-κB inhibition can uncouple hypertension from obesity. To do this, we first did experiments using virus-mediated gene delivery of constitutively active IKK-β (IKK-β CA ) to activate NF-κB in the mediobasal hypothalamus. We preimplanted normal chow-fed, adult C57BL/6 mice with a telemetric blood pressure transmitter; after post-implantation recovery, they received mediobasal hypothalamic injections of either IKK-β CA or control GFP-expressing adenoviruses. Our telemetric monitoring showed that BP values of IKK-β CA -expressing mice gradually increased from day 5 after viral injection, and that these mice became hypertensive on day 7 or 8 after injection (Fig. 1a-d and Supplementary Fig. 1a-d) . IKK-β CA did not markedly affect the heart rates of the mice (Supplementary Fig. 1e,f) . The hypertensive effect of IKK-β CA was independent of body weight or fat mass because the induction of IKK-β CA in this protocol was only short term; this was insufficient to significantly alter these parameters ( Supplementary  Fig. 1g-i) . Furthermore, using high-resolution telemetric recording, we calculated low-frequency blood pressure variability (LF-BPV) and the ratio of low-frequency to high-frequency heart rate variability (LF/HF-HRV), as both parameters can reflect the sympathetic modulation of hemodynamics 29 . LF-BPV ( Fig. 1e) and LF/HF-HRV ( Fig. 1f ) in IKK-β CA -expressing mice were significantly higher than in the control mice, suggesting that IKK-β CA upregulated sympathetic activity. Thus, we suggest that activation of hypothalamic IKK-β and NF-κB can acutely cause hypertension independently of a change in body weight.
In parallel, we examined whether NF-κB inhibition in the mediobasal hypothalamus could reverse obesity-related hypertension. Inhibitor of κB α subunit (IκBα) is a NF-κB-specific inhibitor that undergoes protein degradation in response to IKK-β activation [30] [31] [32] [33] . Therefore, we used viral delivery of dominant-negative IκBα (IκBα DN ) to suppress hypothalamic NF-κB in C57BL/6 mice with chronic, severe obesity induced by 6 months of feeding with a high-fat diet (HFD). With the procedure described above, we analyzed the acute effects of NF-κB loss of function on the blood pressure of HFD-fed mice and matched chow-fed mice. Concomitant with HFD-induced obesity ( Supplementary Fig. 1g -i), we found that the control HFD-fed mice had higher blood pressure levels than control chow-fed mice (Fig. 1c,d and Supplementary Fig. 1a-d) . In contrast, hypothalamic delivery of IκBα DN significantly reduced obesity-related hypertension ( Fig. 1c,d Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-β and NF-κB l e t t e r S and Supplementary Fig. 1a-d) . Also, whereas chronic HFD feeding elevated both LF-BPV and LF/HF-HRV, both changes were blocked by the expression of IκBα DN (Fig. 1e,f) . Notably, we found that body weight and adiposity of HFD-fed mice were not significantly affected by the short-term IκBα DN expression ( Supplementary Fig. 1g-i) ; therefore, the acute hypotensive effect of NF-κB inhibition did not involve the long-term action of hypothalamic NF-κB inhibition in changing body weight 26 . In addition, IκBα DN did not affect normal blood pressure in chow-fed mice (Fig. 1c,d and Supplementary  Fig. 1a-d) , which is consistent with the previous finding that hypothalamic NF-κB is mostly inactive under normal chow feeding 26 .
We also examined whether hypothalamic delivery of IKK-β CA could escalate hypertension in mice with HFD-induced obesity. We found that the blood pressure-raising effect of IKK-β CA was minor in HFD-fed mice that had already developed hypertension ( Supplementary Fig. 2a-d) . The lack of an additive hypertensive effect under these conditions suggests that the hypertensive mechanism of obesity is mediated substantially by the activation of hypothalamic IKK-β and NF-κB.
In addition to viral injection, we adopted a pharmacologic approach to instantly activate hypothalamic IKK-β and NF-κB. We implanted normal chow-fed C57BL/6 mice simultaneously with a blood pressure transmitter and an injection cannula into the third ventricle. After postoperative recovery, mice received an injection of tumor necrosis factor-α (TNF-α) at various doses. Telemetric recording revealed that TNF-α significantly elevated systolic ( Fig. 2a) , diastolic ( Fig. 2b) and mean ( Fig. 2c) blood pressure values and that the hypertensive effect of TNF-α was manifested in a dose-dependent manner ( Fig. 2d) . TNF-α also significantly increased LF-BPV and LF/HF-HRV ( Fig. 2e,f) , thereby indicating that sympathetic upregulation underlies the hypertensive action of TNF-α. Consistent with these results, TNF-α injection increased norepinephrine release into the blood (Fig. 2g) . To test whether sympathetic upregulation could account for the hypertensive role of TNF-α, we intraperitoneally (i.p.) injected the α-adrenergic antagonist prazosin 45 min before a brain injection of TNF-α. Indeed, we found that prazosin completely prevented TNF-α from causing hypertension ( Fig. 2h-j) . Thus, we suggest that TNF-α, an obesity-associated cytokine and a pivotal activator of IKK-β of systolic blood pressure (a), diastolic blood pressure (b) and mean blood pressure (c); dose-dependent increases (∆) in mean blood pressure averaged over a 15-min peak and NF-κB, leads to the neural induction of hypertension in mice, regardless of changes in feeding or body weight.
Subsequently, we asked which neuronal subpopulations in the mediobasal hypothalamus might mediate the hypertensive response of IKK-β and NF-κB activation. We focused on two neuronal subtypes that are crucially involved in obesity development: POMC neurons and NPY/AGRP neurons (coexpressing neuropeptide Y (NPY) and agouti-related peptide (AGRP)). We first examined whether IKK-β and NF-κB in POMC neurons and NPY/AGRP neurons responded to TNF-α similarly. We detected POMC neurons and NPY/AGRP neurons using two lines of reporter mice, Pomc-ROSA mice (Pomc-Cre mice crossed with ROSA-Flox-STOP-Flox-YFP mice) and NPY-GFP mice (GFP under the control of the NPY promoter), in which POMC neurons and NPY/AGRP neurons are fluorescently labeled, respectively. We profiled IKK-β activation in these neurons in response to TNF-α using immunostaining of phosphorylated IKK-β (at Tyr188). Basal expression of phosphorylated IKK-β was barely detectable in the hypothalamus except in a few cells in the median eminence ( Supplementary Fig. 3) . On TNF-α stimulation, IKK-β phosphorylation was evidently induced in the arcuate nucleus, median eminence, ventromedial nucleus and tanycyte ependyma ( Supplementary  Fig. 3) . TNF-α-induced IKK-β phosphorylation was either modest or negligible in other hypothalamic regions (Supplementary Fig. 3) . We examined POMC neurons in the arcuate nucleus and found that induction of IKK-β phosphorylation by TNF-α occurred in the majority of POMC neurons (Fig. 3) . In contrast, induction of IKK-β phosphorylation by TNF-α occurred in far fewer NPY/AGRP neurons (Supplementary Fig. 4) . Hence, we suggest that IKK-β and NF-κB are differentially activated in POMC neurons and NPY/AGRP neurons by TNF-α.
Under basal conditions, we found that IκBα was abundant throughout hypothalamic neurons, including in POMC neurons (Fig. 3b,d) .
The strong baseline expression of IκBα indicates that IKK-β and NF-κB are normally inactive in hypothalamic neurons, as observed previously 26 . However, TNF-α injection via the third ventricle clearly induced IκBα protein degradation in the majority of POMC neurons (Fig. 3b,d) . Induction of IκBα degradation by TNF-α was also evident in the ventral medial nucleus and the dorsal medial nucleus, but it was not evident in the paraventricular nucleus or the lateral hypothalamic region (Supplementary Fig. 5 ). All these data corroborated the spatial pattern of IKK-β phosphorylation induced by TNF-α ( Fig. 3a and Supplementary Fig. 3) . Altogether, IKK-β and NF-κB in POMC neurons are sensitive to activation by TNF-α, suggesting that hypothalamic POMC neurons are mechanistically relevant to the development of obesity-related hypertension caused by hypothalamic inflammation.
We next explored the molecular basis of the differential activation of IKK-β and NF-κB in POMC and NPY/AGRP neurons by TNF-α. Because both TNF-α receptor 1 (TNF-α R1) [30] [31] [32] [33] and TNF-α receptor 2 (TNF-α R2) 34 convey TNF-α stimulation to IKK-β and NF-κB activation, we examined the distribution patterns of these two receptors in the hypothalamus. We detected very little TNF-α R1 in hypothalamic neurons, whereas we found that it was expressed mostly in non-neuronal cells, including in tanycytes localized in the median eminence and the third ventricle wall (Supplementary Fig. 6) . In contrast, TNF-α R2 was abundantly expressed in neurons of the hypothalamic arcuate nucleus (Supplementary Fig. 7) . Immunostaining with the fluorescent reporter mice revealed that TNF-α R2 was expressed in POMC neurons but only modestly in NPY/AGRP neurons (Supplementary Fig. 7) . TNF-α R2 was detected in the membrane as well as in the cytoplasm of the neurons (Supplementary Fig. 7) , indicating that TNF-α R2 in the hypothalamus underwent constant protein synthesis with a fast protein turnover rate. Overall, TNF-α R2 distribution and TNF-α-induced IKK-β phosphorylation in the hypothalamus spatially correlated with each other ( Fig. 3a and  Supplementary Fig. 7) .
Supported by the IKK-β and NF-κB signaling profile in POMC neurons, we tested whether the inhibition of IKK-β and NF-κB in POMC neurons could prevent the acute induction of hypertension by TNF-α. To do so, we bred Ikbkb lox/lox mice 26 with Pomc-Cre mice 35 (mice expressing Cre under a Pomc promoter) to generate a mouse line, termed Pomc-Ikbkb lox/lox , with IKK-β ablated in POMC neurons. For comparison, we also included a mouse line with IKK-β ablated in AGRP neurons (termed Agrp-Ikbkb lox/lox mice); we generated these mice by crossing Ikbkb lox/lox mice with Agrp-Cre mice as described previously 26 . We preimplanted all mice with a cannula into the third ventricle at ~2 weeks before the pharmacological injection. We maintained l e t t e r S these mice on normal chow feeding, and food intake and body weight of age-matched Pomc-Ikbkb lox/lox mice, Agrp-Ikbkb lox/lox mice and control Ikbkb lox/lox mice were comparable (Supplementary Fig. 8a,b) .
In response to TNF-α injection, systolic, diastolic and mean blood pressure values in Agrp-Ikbkb lox/lox mice and control mice increased similarly (Fig. 4a-c) . However, blood pressure in Pomc-Ikbkb lox/lox mice did not increase after TNF-α stimulation (Fig. 4a-c) . Further, although TNF-α upregulated sympathetic modulation of hemodynamic response in Agrp-Ikbkb lox/lox mice and in the control Ikbkb lox/lox mice, it did not do so in Pomc-Ikbkb lox/lox mice (Fig. 4d,e ). Because the protocol of this experiment required only a few hours, the antihypertensive effect shown in Pomc-Ikbkb lox/lox mice was unrelated to changes in feeding or body weight. Thus, we suggest that the inhibition of IKK-β and NF-κB in mouse POMC neurons has a key role in preventing TNF-α-induced hypertension in a manner that is independent of feeding or body weight. Finally, we used Pomc-Ikbkb lox/lox mice to test whether IKK-β ablation in POMC neurons could prevent the induction of hypertension by obesity. We maintained mice under long-term HFD feeding. Unlike Agrp-Ikbkb lox/lox mice, which showed a lesser degree of HFD-induced obesity as previously described 26 , Pomc-Ikbkb lox/lox mice developed HFD-induced obesity in a similar manner to that of the control Ikbkb lox/lox mice (Supplementary Fig. 8c) . Thus, compared to AGRP neurons, inhibition of IKK-β and NF-κB in POMC neurons per se is insufficient to affect body weight. However, despite the development of dietary obesity, Pomc-Ikbkb lox/lox mice were significantly protected from the induction of hypertension under conditions of HFD-induced obesity (Fig. 4f) . Taken together, we found that the pathological effects of obesity-associated inflammation through different types of neuronal subpopulations in the mouse hypothalamus can be divergent. Although IKK-β and NF-κB in AGRP neurons is crucial for mediating metabolic disorders through neuroendocrine alterations 26 , the disease relevance of IKK-β and NF-κB in POMC neurons involves sympathetic alterations that can lead to obesity-related hypertension and, potentially, to CVD (Fig. 4g) .
The so-called 'metabolic syndrome' refers to a spectrum of metabolic disorders, such as obesity, dyslipidemia, insulin resistance and hypertension, all of which increase the risk for developing cardiovascular disease 9, 11, 18, 19 . A common feature of these health problems is a sustained but low-grade inflammation in the circulatory system and in many peripheral tissues 14, 24, 25 . Using a combination of viral, genetic and pharmacologic approaches, we showed that the proinflammatory IKK-β and NF-κB pathway in the hypothalamic arcuate nucleus in general, or in POMC neurons in particular, has a key role in obesityrelated hypertension. In conjunction with our recent research 26 , this current research shows that IKK-β and NF-κB-mediated hypothalamic inflammation can lead to obesity-induced CVD and other metabolic disorders (such as insulin resistance and type 2 diabetes) in a divergent manner (Fig. 4g) .
Metabolic diseases and cardiovascular disorders are two major types of obesity-associated problems, and these obesity comorbidities are often intertwined. Our findings in the present study suggest that hypothalamic activation of IKK-β and NF-κB can direct obesityassociated cardiovascular disorders and metabolic diseases in a parallel manner, and that inhibition of IKK-β and NF-κB in POMC neurons can disentangle these two categories of problems to a certain extent. A potential divergence point between the metabolic and cardiovascular consequences of obesity can be determined by the impact of the hypothalamus on endocrine versus neural pathways. Although the connection between POMC neurons and the sympathetic nervous system might not be prominent in normal physiology, our data suggest that this connection can be reinforced under obesogenic conditions by disease factors such as hypothalamic IKK-β and NF-κB activation. Indeed, a few recent studies have begun to recognize a potential role of the hypothalamic POMC-melanocortin system in modulating the sympathetic pathway that affects blood pressure balance 36, 37 . We also realize that, although hypertension is often a ramification of dietary obesity, there are certain obesity models, such as melanocortin-4 receptor knockout mice 38 , that are not clearly accompanied by hypertension. In light of this study, it may be necessary to examine whether POMC neurons are under the protection of anti-inflammatory properties in normotensive obesity models. 
MeTHODs
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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